Exact Sciences planning $125 million follow-on

Diagnostic company Exact Sciences Corp. (NASDAQ:EXAS) proposed late Wednesday to raise $125 million in a follow-on underwritten by Jefferies; Goldman Sachs; Baird; William Blair; and Canaccord. Last week, the Molecular and Clinical Genetics Panel of FDA's Medical Devices Advisory Committee voted 10-0 that the benefits of Exact Science's Cologuard outweigh the product's risks as an adjunctive screening test in patients who are at average risk for colorectal cancer. Cologuard is under a pilot parallel FDA/CMS review (see BioCentury Extra, March 27). ...